WASHINGTON (March 24)  -- Today, Incubate and the National Security Commission on Emerging Biotechnology (NSCEB) convened venture capital investors, NSCEB commissioners and staff, and congressional offices on Capitol Hill for a roundtable on strengthening U.S. leadership in biotechnology. The discussion provided NSCEB and participating lawmakers' offices with a candid investor perspective on federal policy conditions that influence whether early-stage biotech research and dev

As Japanese Prime Minister Sanae Takaichi prepares for a summit with President Trump in Washington next week, Incubate is proud to reflect on the deep and sustained engagement we have built with Japan's life sciences ecosystem and to reaffirm our commitment to advancing the US-Japan biotech relationship for years to come. For Incubate, Japan is not a new frontier. It is a long-standing partner, and our work there has been built deliberately, engagement by engagement, over the

WASHINGTON (January 28)  -- Yesterday, the Centers for Medicare & Medicaid Services announced  the third round of drugs subject to Medicare price controls under the Inflation Reduction Act. The new government-set prices will affect medicines covered under both Medicare Part D and Medicare Part B and take effect in 2028.   Incubate's executive director, John Stanford, issued the following statement in response:   "The latest announcement from CMS represents a significant expan

WASHINGTON ( January 15 ) -- Today, President Trump unveiled  his "Great Healthcare Plan," including a proposal for Congress to codify Most Favored Nation  (MFN) drug pricing into law. This policy would import foreign government price controls into the U.S. market and threaten the innovation ecosystem responsible for delivering new cures and lifesaving treatments.    Incubate's executive director, John Stanford, issued the following statement in response to the announcement: